GHK-Cu is a copper-bound, three-amino-acid peptide studied mainly for skin and wound healing, sold widely in both cosmetic creams and injectable “research chemical” form. It’s the only compound on this site with a real randomised, placebo-controlled human trial, and that trial, in venous stasis ulcers, found the copper cream performed no better than an inert vehicle. Every positive human claim in circulation traces back to unpublished conference abstracts, a defunct journal, a book chapter, or a press release, not to a peer-reviewed controlled study.
Ask about GHK-Cu
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Copper-bound tripeptide (GHK-Cu); distinct from the free tripeptide GHK, which is routinely conflated with it |
| Primary research interest | Skin/wound healing, collagen synthesis; secondary interest in hair density and lung disease |
| Highest available evidence | Tier 1, one published, randomised, evaluator-blinded human trial (negative result, no better than placebo) |
| Human research available | Yes, but limited to three controlled/semi-controlled studies, two of them clean negatives and one uncontrolled |
| Development status | Discontinued as a drug candidate (Iamin, ProCyte, 1990s); currently sold only as a cosmetic ingredient and an unapproved injectable |
| Regulatory status | Not an approved drug anywhere, by any route; cleared only as a cosmetic ingredient at industry-surveyed concentrations (far below what circulates online) |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | GHK-Cu |
| Alternative names | Copper Tripeptide-1, Prezatide copper acetate, Iamin, GraftCyte (also confused in the marketplace with the copper-free peptide GHK / Tripeptide-1) |
| Peptide sequence | Gly-L-His-L-Lys, 1:1 copper(II) complex |
| Amino-acid length | 3 residues + bound Cu(II) |
| Molecular formula | C14H22CuN6O4 (neutral 1:1 complex); the copper-free peptide GHK is C14H24N6O4 |
| Molecular weight | ≈401.9 g/mol (GHK-Cu); ≈340.38 g/mol (free GHK) |
| CAS Registry Number | 89030-95-5 (GHK-Cu); 49557-75-7 (free GHK); two different CAS numbers routinely used interchangeably by vendors |
| PubChem CID | 71587328 (GHK-Cu); 73587 (free GHK) |
| Chemical modifications | Copper(II) chelation, roughly 16% copper by mass |
| Peptide class | Copper-peptide complex; drug name prezatide |
| Primary biological target | Not established; no receptor identified for either GHK or GHK-Cu |
| Developer / originator | Discovered in human plasma, 1970s; acetate salt developed by ProCyte Corp as a wound-healing drug (Iamin), 1990s |
| Development status | Discontinued; never reached drug approval |
What it is
GHK is a three amino acid peptide, glycyl-L-histidyl-L-lysine. GHK-Cu is that peptide bound to a copper ion. They are different substances and the literature conflates them constantly. In cosmetic labelling the copper-free peptide is Tripeptide-1 and the complex is Copper Tripeptide-1, and the two are routinely treated as interchangeable.
The complex is roughly 16 percent copper by mass. That number matters later, because it is the difference between reading GHK-Cu as a peptide and reading it as a copper delivery vehicle, and the literature has never settled which it is.
GHK was found in human plasma in the 1970s and published as GHL for its first decade, which is why a search for GHK misses the foundational papers. Its drug name is prezatide, and the copper acetate form was developed as a wound-healing drug, Iamin, by ProCyte in the 1990s. That programme never reached approval.
One detail from the early work sits awkwardly beside how it is marketed now. GHK was originally characterised as a growth factor for hepatoma cells, its discoverer describing effects across cell types ranging from growth stimulation to outright toxicity.
How it works
No receptor for GHK or GHK-Cu has been identified. Every pathway proposed for it is downstream, and the proximal binding event is unknown apart from two single-group claims, to SIRT1 and peroxiredoxin 6.
What has actually been measured
GHK binds copper about as tightly as albumin and can strip it from albumin transport sites (Lau 1981). In fibroblast culture it raises collagen and glycosaminoglycan synthesis, peaking around one nanomolar (Maquart 1988). In rat wound chambers it increases matrix accumulation and collagen messenger RNA where an inactive control tripeptide does not (Maquart 1993).
Is the peptide necessary, or is it carrying copper?
This is the central unresolved question and the evidence contradicts itself in both directions.
Pointing toward copper: the MMP-2 stimulation attributed to GHK-Cu was reproduced by copper ions alone and not by the peptide. In a rabbit corneal model, GHK, ceruloplasmin, its fragments and heparin all induced vessel growth, and only when copper-bound. And the permeation study cited everywhere as proof GHK-Cu penetrates skin measured copper, not intact peptide (Hostynek 2010).
Pointing the other way: one study found copper-free GHK reproduced the effects of the copper complex in keratinocytes. That result would settle a great deal if it held, and in fourteen years nobody has followed it up.
The flagship mechanism points the wrong way
GHK-Cu is widely described as working through TGF-beta activation. The primary data mostly says the opposite. One 2012 paper reports a TGF-beta activation signature. Against it: the foundational rat wound study found no increase in TGF-beta messenger RNA, and studies in 2007, 2014 and 2023 all found the copper complex decreased TGF-beta 1. The direction of the mechanism most often cited for this molecule is contested, and most primary measurements point down.
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use | Route | Amount reported | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|
| Venous stasis ulcer healing (human trial) | Topical | 0.4% tripeptide-copper cream | Not stated in abstract | Not stated in abstract | Published human RCT, result: no better than placebo |
| Skin aging (dominant circulating figure) | Topical | 1% to 3% by weight | Once or twice daily | Continuous | Community / vendor reported |
| Skin aging (minority circulating figure) | Topical | 0.05% to 1% by weight | Once or twice daily | 8-12 weeks | Community / vendor reported |
| General systemic use | Subcutaneous | 1 to 2 mg | Daily, or 5 days on/2 off | 4-6 weeks on, 2-4 off | Community / vendor reported |
| Actual surveyed cosmetic-industry use (for comparison) | Topical | 0.00002% to 0.001% | N/A | N/A | Cosmetic Ingredient Review panel survey, three to five orders of magnitude below circulating figures |
Potential benefits and research applications
Wound and skin healing
This is the primary research application and the one with an actual randomised controlled human trial behind it, a genuine rarity on this site, and the result is a clean negative. Evidence tier: one randomised, evaluator-blinded human trial (negative); animal work (rat wound chambers, positive on tissue markers, not clinical healing rate). Has been shown to increase collagen synthesis markers in cell culture and animal wound models; has not been shown effective in the one controlled human trial that tested it directly against placebo.
Hair density
A widely repeated claim with an unusually clear sourcing problem. The study cited everywhere as evidence GHK-Cu grows hair actually tested a different peptide, AHK-Cu, with its own distinct CAS number, despite a title that reads as though it covers GHK-Cu. The only genuine GHK-Cu hair data is a two-page 1991 meeting proceeding in mice, authored by the company developing the product. Evidence tier: largely misattributed to a different compound; the one authentic data point is company-authored and unpublished as a full paper. Has not been established; the primary citation used to support this claim does not actually support it.
Anti-aging and collagen density claims (topical)
The claim that GHK-Cu creams tighten skin, reduce wrinkles, and increase skin density appears in nearly every consumer-facing source. Tracing the reference list of the most-cited review back to its sources finds four items: two never-peer-reviewed one-page conference abstracts from a 2002 dermatology meeting, a 1998 pilot study in a now-defunct, never-indexed journal, and a 2005 book chapter. Two of the four share authors who were scientific-affairs staff at a copper-peptide skincare manufacturer at the time. Evidence tier: industry-originated grey literature, not peer-reviewed human data. Has been reported in industry-affiliated sources; has not been established in any independent, peer-reviewed, controlled human study.
Lung disease (emphysema, fibrosis)
An independent research line from Chinese respiratory groups has tested GHK-Cu across emphysema, fibrosis, silicosis, acute lung injury, and asthma models, entirely in mice via intraperitoneal injection. Evidence tier: published animal research, genuinely independent of the cosmetic-industry literature. May support reduction of oxidative stress and inflammation in mouse lung injury models; has not been tested in any human lung condition.
Research evidence
Human evidence: three controlled trials, two of them negative
The trial is Bishop 1992 in the Journal of Vascular Surgery. Prospective, randomised, evaluator-blinded, three arms, 86 evaluable patients with chronic venous stasis ulcers, comparing 0.4 percent topical tripeptide-copper cream against silver sulfadiazine against an inert vehicle. The copper cream was indistinguishable from placebo and silver sulfadiazine beat both. It is the largest and most rigorous human trial of GHK-Cu ever published, a clean null, and effectively absent from the marketing literature and from the review series that built this compound reputation.
The second, Miller 2006, tested a topical regimen with and without GHK-Cu after CO2 laser resurfacing in thirteen completers. No difference in erythema resolution, no improvement in wrinkles or skin quality on objective evaluation. The only positive was patient-reported satisfaction on a questionnaire.
The third is not really a GHK-Cu trial. Kapoor and Shome 2018 injected a six-component scalp formulation, one component being copper tripeptide-1, open-label, single-arm, no control and no vehicle group. Hair measures improved. Nothing in that can be assigned to the copper peptide, and the authors own the clinic and the formulation. It remains the only published human study in which GHK-Cu was injected.
Where the positive human claims come from
The claim that GHK-Cu creams tighten skin, reduce wrinkles and increase skin density appears in every review and in almost all consumer writing. Trace the reference list of the most-cited review and the entire human basis is four items.
- A one-page abstract from the 2002 American Academy of Dermatology meeting, 71 women, 12-week facial cream. Never peer-reviewed, not in PubMed, no methods, no data tables, no statistics.
- A second one-page abstract from the same 2002 meeting, 41 women, eye cream. Same status.
- A 1998 self-described pilot in a journal that no longer exists and was never PubMed-indexed, reporting percentages improved with no stated denominator.
- A 2005 book chapter, which is not a primary research report.
Two of those four share authors who were then scientific-affairs staff at the manufacturer of a copper-peptide line. The review series propagating the claims lists its authors at the research department of a company selling copper-peptide skincare, while declaring no external funding and no conflict of interest. A 2023 result reported as a randomised controlled trial in 21 women, showing a 28 percent rise in subdermal echogenic density, exists only as a press release.
Stated plainly: no positive result for GHK-Cu comes from an independent, peer-reviewed, controlled human trial. The two peer-reviewed controlled trials are null. The positive human material is industry-originated grey literature.
Registered trials
One interventional efficacy trial has ever been registered, recruiting from February 2026: randomised, double-blind, vehicle-controlled, 60 healthy volunteers, two punch wounds each, topical gel for 14 days, endpoint time to re-epithelialisation, one site in Shenzhen. No results posted, and its own description concedes the rationale is preclinical literature.
A second, not yet recruiting, will test whether a wearable patch marketed on a GHK-Cu premise actually raises blood levels of it. It excludes people with Wilson disease, the only registered acknowledgement in this field that copper loading is a plausible hazard.
There are none at all for diabetic foot ulcer, venous leg ulcer, pressure ulcer, burns, any hair or cosmetic endpoint, any lung condition, any cancer, any cognitive or musculoskeletal condition, or for injectable GHK-Cu by any route.
Preclinical evidence
The animal and cell literature is substantial, including an independent lung programme from Chinese respiratory groups across emphysema, fibrosis, silicosis, acute lung injury and asthma, all by intraperitoneal injection in mice.
Two results run against the grain. A 1995 guinea-pig study found slower skin reorganisation and delayed fibroblast activation. And the closest thing to a musculoskeletal study, a rat ACL model with intra-articular injection, found reduced laxity at six weeks but nothing at twelve, and no difference in ultimate load, gait or histology at any point. The effects did not last once treatment stopped.
Claims that trace to a different molecule or to no experiment
Three citations in this literature do not support the claim attached to them.
- The hair growth paper. The study cited everywhere as evidence GHK-Cu grows hair tested AHK-Cu, a different peptide with a different CAS number. Its title says tripeptide-copper complex, which reads as GHK-Cu. It used molar concentrations in follicle culture and described no topical formulation, so the 0.1 to 0.3 percent figures cited to it appear nowhere in it. The only genuine GHK-Cu hair data is a two-page 1991 meeting proceeding in mice, first-authored from the company developing the product.
- The colon cancer claim. The paper cited for GHK suppressing metastasis genes queried a gene-expression database and found GHK computationally capable of reversing a signature. No GHK touched any cell or patient. A database prediction reported as an experiment.
- The COPD and radiation claims. Same pattern twice. The COPD signature reversal is a database prediction plus cultured fibroblasts; restoring vitality in radiation patients is cell culture from donor explants. No patient was treated in either.
The most repeated fact about this molecule has no published source
Nearly every article, product page and review states that plasma GHK is about 200 nanograms per millilitre at age 20 and falls to 80 by age 60. Following the citation leads to one reference: an unpublished 1973 doctoral thesis by the man who discovered the molecule. Never peer reviewed, no sample size, no cohort description, no assay validation, no error bars, not in PubMed, not independently retrievable.
The peer-reviewed human measurements that do exist do not reproduce that curve. They show something different: plasma GHK is lower in people with COPD and in asthma than in age-matched controls. Association findings in tiny samples, and the most solid human data in this field.
The concentration problem
Topical figures split into two clusters that do not overlap. The dominant one is 1 to 3 percent by weight, a minority cluster 0.05 to 1 percent. They differ by up to sixty-fold, both presented as standard, because no dose-ranging study exists to arbitrate.
Against that, the Cosmetic Ingredient Review panel surveyed actual industry use and found Tripeptide-1 at 0.00002 to 0.001 percent. The circulating figures are three to five orders of magnitude higher, and the panel safety clearance is explicitly bounded to present practices of use and concentration, which is the 0.001 percent end.
The cell literature makes this harder rather than easier. The fibroblast dose-response is biphasic: synthesis peaks around one to ten nanomolar and returns toward control above that. A related copper tripeptide stimulates below ten micromolar and inhibits above it. More is not better in any primary measurement of this molecule, and the circulating figures sit far above the window where anything was observed.
GHK-Cu in blends: KLOW, GLOW and related mixes
Most people who search for GHK-Cu now meet it inside a blend. The two best known are KLOW (GHK-Cu, KPV, BPC-157 and TB-500) and GLOW (the same mix without KPV). Both are vendor names, not scientific or regulatory terms, and neither has a standard formula. Their own pages cover composition, why the names caught on, and the arithmetic of what a vial contains.
Two points matter here. First, GHK-Cu is the largest ingredient by mass in the commonly stated versions of both, so the copper peptide is most of what is in the vial. Second, the evidence for GHK-Cu on this page does not transfer to a blend. The controlled human trials above used topical formulations, and no published study has tested GHK-Cu together with any of the other peptides, including what the copper does in a shared vial (see the handling section below).
Related mixes with their own pages: the GHK-Cu and BPC-157 pairing (two of the three GLOW ingredients) and Wolverine (BPC-157 with TB-500, no copper peptide). The uncomplexed form without copper has its own entry as plain GHK, which is a different substance from the one in these products.
Safety
There is no human pharmacokinetic study of GHK or GHK-Cu by any route. No half-life, no clearance, no bioavailability figure. The circulating half-life numbers, usually 30 minutes free and four to six hours albumin-bound, are unattributed, and the papers cited beside them contain no half-life value.
The only pharmacokinetic data of any kind is a single intravenous dose in rats from 1997, whose headline finding is rapid degradation to the dipeptide His-Lys. Whether administered GHK-Cu survives intact in plasma, or hands its copper straight to albumin and histidine as the binding chemistry predicts, is unknown, and that one unknown sits under every systemic dosing rationale.
The copper is the part worth thinking hardest about. At 16 percent copper by mass, the circulated 1.7 mg per day is about 270 micrograms of elemental copper injected daily, against an oral adult intake of 900. That understates it, because copper homeostasis is regulated at the intestine and injection bypasses that. Nobody has measured serum copper, ceruloplasmin or liver copper in anyone injecting it.
On toxicology the Cosmetic Ingredient Review panel stated its gaps directly: data on carcinogenicity were not found in the published literature, nor on reproductive and developmental toxicity, and no penetration data were identified. Separately, no acute or repeat-dose study, no no-effect level and no lethal dose figure appears in PubMed.
FDA’s earlier Category 2 listing of the injectable form stated: compounded injectable GHK-Cu may pose risk for immunogenicity through aggregation and peptide-related impurities, with limited human data to inform safety.
One more unexamined question. Closely related copper tripeptides act as peroxidase mimics and generate reactive oxygen species with ascorbate and oxygen, in one case irreversibly inactivating an enzyme. Whether GHK-Cu does the same in the body is untested. The review series for this molecule recommends pairing it with vitamin C, the exact combination that drives that chemistry.
Regulatory status
GHK-Cu is not an approved drug for any indication, in any form, by any route, anywhere, and there is no pending application. Prezatide copper acetate is a registered development entity from the ProCyte programme that never reached approval.
In cosmetics the picture is different and frequently misdescribed. Copper Tripeptide-1 sits in the European Commission ingredient database as skin conditioning, in no restriction annex, so there is no EU maximum. The Cosmetic Ingredient Review panel concluded it is safe in present practices of use and concentration, but that panel is industry-funded and self-regulatory, and FDA does not pre-approve cosmetic ingredients. Claims that GHK-Cu is FDA approved are wrong in both directions.
GHK-Cu is not on the 503A bulk drug substances list. FDA’s 503A categories page (dated May 14, 2026, read October 8, 2026) lists GHK-Cu except for injectable routes of administration in Category 1, substances under evaluation. The same page says GHK-Cu was removed from Category 1 on April 22, 2026 after the nominators withdrew, then added back after a nominator clarified on May 5, 2026 that it had meant to withdraw only the injectable route. The injectable form therefore has no active nomination, and withdrawal is not a clearance. FDA states it intends to consult the Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027, and Category 1 placement is neither an approval nor a finding of safety. Compounding under 503A requires a pharmacopoeial monograph, membership of an approved drug, or a place on that list. GHK-Cu meets none of the three and is absent from 503B entirely.
Handling and identity
Two CAS numbers circulate and suppliers use them interchangeably, one for the free peptide and one for the copper complex. A certificate of analysis quoting the free-peptide number for a product sold as GHK-Cu describes a different substance. Whether the powder is the 1:1 complex, the acetate salt, a mixture, or free peptide plus a copper salt is not verifiable from a label.
The peptide holds up in water between pH 4.5 and 7.4 but is cleaved under oxidative stress. Shelf life of reconstituted injectable GHK-Cu has no published source, and neither does copper speciation in bacteriostatic water or what the copper does in a multi-peptide vial alongside BPC-157, TB-500 and KPV (the mix sold as KLOW, or as GLOW without KPV). Nobody has published on that last question at all.
The 1980 Nature paper names the molecule glycyl-L-lysine in its own abstract, leaving the histidine out, and that error has propagated into citation databases.
Frequently asked questions
What is GHK-Cu?
A copper-bound, three-amino-acid peptide studied mainly for skin and wound healing, sold as both a cosmetic ingredient and an unapproved injectable.
Is GHK-Cu the same as GHK?
No. GHK is the free peptide; GHK-Cu is that peptide bound to a copper ion, two different substances with two different CAS numbers, though vendors and even some certificates of analysis use the numbers interchangeably.
Has GHK-Cu been tested in a real human trial?
Yes, this is one of the few compounds on this site with an actual randomised, controlled human trial. It found the copper cream performed no better than an inert vehicle for healing venous stasis ulcers.
Is GHK-Cu FDA approved?
No, in any form, by any route. It’s cleared only as a cosmetic ingredient at industry-surveyed concentrations, which is not the same thing as drug approval.
What dosage has been studied in humans?
A 0.4% topical cream (the negative ulcer trial) and an undisclosed topical concentration in a laser-resurfacing study. No study has established an injectable human dose of any kind.
What dosage commonly circulates online?
Topically, 1 to 3 percent by weight is most common, though a competing 0.05 to 1 percent figure also circulates, the two disagree by up to sixty-fold. Injectable protocols commonly cite 1 to 2 mg daily. All of these sit far above documented actual cosmetic-industry concentrations.
Does GHK-Cu really grow hair?
The study most often cited for this tested a different compound (AHK-Cu), not GHK-Cu. The actual GHK-Cu hair evidence is a single unpublished 1991 meeting proceeding from the product’s own developer.
What side effects have been reported?
No formal human toxicology exists for this compound. The main documented concern is copper load from injectable use, nobody has measured whether repeated injection raises serum copper or affects the liver, and the injectable route bypasses the body’s normal copper-regulation system.
How strong is the evidence overall?
Weak for the specific claims driving most real-world interest (skin anti-aging, hair growth), the human trial evidence is either negative or untraceable to a real study. Better for basic fibroblast-stimulation biology, though even the central mechanism (TGF-beta) is contested by the primary data.
What remains unknown?
Whether the peptide or the copper is doing the biological work; whether injected GHK-Cu survives intact in the body; what a safe injectable dose or cumulative copper exposure looks like; and what’s actually inside a commercially sold vial, given how loosely the identity is documented.
Bottom line
GHK-Cu is unusual among unapproved research compounds in actually having a real, well-designed human trial behind it, and that trial found it didn’t work. Beyond that one clean result, the pattern here is consistent: nearly every positive human claim traces back to something other than a peer-reviewed controlled study, a conference abstract that was never indexed, a defunct journal, a book chapter, a press release, or in the case of the hair-growth claim, a different molecule entirely. What’s genuinely published: solid cell-culture and animal mechanistic work on collagen and matrix synthesis, one clean negative human trial, and an independent line of mouse lung-injury research unrelated to the cosmetic story. What’s merely reported online: essentially every specific dosage figure in circulation, both topical and injectable, none of which is supported by the concentrations the compound has actually been shown to do anything at in a laboratory. GHK-Cu is not FDA-approved in any form, its central mechanism is scientifically contested, and the copper-load question for injectable use has never been studied in a single human being.
Reported amounts and the evidence behind them: GHK-Cu dosage: topical percentages and injected amounts reported online.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Skin ageing, dominant figures | Topical | 1% to 3% | Once or twice daily | Continuous, no cycling |
| Skin ageing, minority figures | Topical | 0.05% to 1% | Once or twice daily | 8 to 12 weeks |
| Hair density | Topical | 0.1% to 0.3% | Once daily | 12 weeks or longer |
| General | Subcutaneous | 1 to 2 mg | Daily, or 5 days on 2 off | 4 to 6 weeks on, 2 to 4 off |
| As part of the GLOW or KLOW blend | Subcutaneous | About 1.67 mg per dose | Once daily | 4 to 6 weeks |
GHK-Cu is the compound on this site where circulating figures and documented practice are furthest apart, and the gap is not a matter of opinion. The dominant topical figure is 1 to 3 percent by weight. A minority cluster runs 0.05 to 1 percent. Both are presented as standard and they differ by as much as sixty-fold, because there is no dose-ranging study to arbitrate.
The Cosmetic Ingredient Review panel surveyed what the cosmetic industry actually puts in products and found the copper-free peptide used at 0.00002 to 0.001 percent. The circulating figures are three to five orders of magnitude higher. That panel concluded these ingredients are safe in the present practices of use and concentration, and the 1 to 3 percent products are not within those practices.
The injectable figures cluster at 1 to 2 milligrams daily, with 1.7 milligrams repeated often enough to look like a standard. At roughly 16 percent copper by mass, that is about 270 micrograms of elemental copper injected per day, against an oral adult recommended intake of 900 micrograms. Injection bypasses the intestine, which is where the body regulates copper, and nobody has measured serum copper or ceruloplasmin in anyone doing this.
One more thing the figures do not account for. In fibroblast culture the effect peaks around one to ten nanomolar and declines at higher concentrations, and a 1995 study found reduced fibroblast proliferation at one hundred nanomolar. More is not better in any primary measurement of this molecule.
Note also that the Wolverine blend does not contain GHK-Cu, although it is searched alongside GLOW and KLOW, which do.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Zhang Q, Yan L, Lu J, Zhou X. Glycyl-L-histidyl-L-lysine-Cu attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Front Mol Biosci. 2022. Preclinical, C57BL/6J mice exposed to cigarette smoke for 12 weeks with GHK-Cu injected intraperitoneally at 0.2, 2 and 20 micrograms per gram of body weight per day in saline on alternate days. One of the two mouse lung studies establishing that intraperitoneal alternate day dosing range. PMID 35936787
- Ma WH, Li M, Ma HF, Li W, Liu L, Yin Y, Zhou XM, Hou G. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci. 2019. Preclinical, bleomycin instilled into the trachea of C57BL/6J mice with GHK-Cu injected intraperitoneally at 0.2, 2 and 20 micrograms per gram of body weight per day in PBS on alternate days. The second mouse lung study establishing that intraperitoneal alternate day dosing range. PMID 31809714
- Bishop JB, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. PMID 1495150
- Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth. J Cosmet Laser Ther. 2018. PMID 29482481
- Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981. PMID 7340824
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264
- Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex in rat experimental wounds. J Clin Invest. 1993. PMID 8227353
- Simeon A, et al. Modulation of glycosaminoglycan synthesis by the tripeptide-copper complex. Life Sci. 1992. PMID 1522753
- Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2010. PMID 20721598
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. Note: the molecule tested is AHK-Cu, not GHK-Cu. PMID 17703734
- Hong Y, et al. A susceptibility gene set for early onset colorectal cancer. Clin Exp Metastasis. 2010. Note: the GHK finding is a Connectivity Map database prediction, not an experiment. PMID 20143136
- Buffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts. Arch Int Pharmacodyn Ther. 1995. PMID 8836453
- Endo Y, Miyagi M, Ujiie A. Determination of glycyl-L-histidyl-L-lysine in rat plasma after intravenous administration. J Chromatogr B. 1997. PMID 9187381
- Pickart L, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980. PMID 7453802
- Pickart L, Thaler MM. Growth-modulating tripeptide glycylhistidyllysine: effects on hepatoma cells and normal hepatocytes. J Cell Physiol. 1980. PMID 6246126
- Zhang X, et al. GHK-Cu and skeletal muscle dysfunction, with plasma GHK measurements in COPD and controls. J Cachexia Sarcopenia Muscle. 2023. PMID 36905132
- Intra-articular GHK-Cu in a rat anterior cruciate ligament reconstruction model. J Orthop Res. 2015. PMID 25731775
- Johnson W Jr, et al. Safety assessment of tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 as used in cosmetics. Cosmetic Ingredient Review Expert Panel. Int J Toxicol. 2018. DOI 10.1177/1091581818807863
- US Food and Drug Administration. Ipamorelin acetate, 503B, listed 29 September 2023, citing immunogenicity risk and serious adverse events including death reported in the literature after intravenous administration. FDA Category 2
- Hudson Biotech. Topical GHK-Cu gel versus vehicle gel in a paired split-wound model. Phase 2, recruiting from February 2026. No results posted. NCT07437586
- LifeWave, Inc. Two-part study of a wearable patch on circulating blood levels of GHK and GHK-Cu. Not yet recruiting. NCT07706361
- Tewari K, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. Scoping review. doi:10.1177/03635465261464420
Compare GHK-Cu with related compounds
Research area: Tissue repair and recovery.